RegulationPriority Review (United States), Breakthrough Therapy (United States), Priority Review (Australia), Special Review Project (China), Fast Track (United States)

Structure/Sequence

Molecular FormulaC19H17F2N3NaO5

InChIKeyNOSILXJBCIUPCT-KIUAEZIZSA-N

CAS Registry1051375-13-3

Clinical Trials associated with Cabotegravir sodium

NCT06854029

/ Not yet recruitingPhase 4IIT

Optimizing Long-Acting Pre-Exposure Prophylaxis and Medications for Opioid Use Disorder Interventions in Carceral Settings

The investigators plan to conduct an R61/33 hybrid type 2 implementation-effectiveness trial that includes 1) a one-year exploratory R61 phase that will enable the development of the intervention protocol needed for the R33 trial phase including concrete R61 phase milestones; 2) a four-year R33 phase that will include a concurrent implementation evaluation and a randomized control trial.

Start Date01 Jun 2026

Sponsor / Collaborator

Duke University

[+4]

NCT07346508

/ Not yet recruitingNot Applicable

Project SPEED - Streamlined Protocol for Early Engagement and Delivery of HIV Prevention With Long-acting Injectable Cabotegravir: A Nurse-driven Protocol

Project SPEED (Streamlined Protocol for Early Engagement and Delivery of HIV Prevention) is a pragmatic, cluster randomized implementation study evaluating a nurse-driven model for delivering long-acting injectable cabotegravir (LAI-CAB) for HIV pre-exposure prophylaxis (PrEP) within local public health departments (LPHDs) in Missouri. Although LAI-CAB is a highly effective HIV prevention strategy, access remains limited in many rural and resource-constrained settings due to workforce shortages and barriers to specialty care.
In this study, LPHDs are randomized to either implement a structured nurse-led PrEP delivery protocol (SPEED intervention) or continue current standard practices. At intervention sites, trained registered nurses assess PrEP eligibility, provide HIV and sexually transmitted infection testing, administer LAI-CAB injections under standing orders, and support ongoing follow-up as part of routine public health services. Control sites continue their usual workflows without additional training or standardized PrEP delivery processes introduced by the study.
The study uses an effectiveness-implementation hybrid type III design and is guided by established implementation science frameworks to evaluate reach, adoption, implementation, and sustainability of the nurse-driven model. Participants receiving care at participating LPHDs are followed for up to 48 weeks.
Project SPEED aims to generate real-world evidence on whether a nurse-driven approach can expand access to long-acting HIV prevention in public health settings, particularly in rural and underserved communities, and to inform scalable strategies for broader implementation of LAI-CAB PrEP.

Start Date01 Apr 2026

Sponsor / Collaborator

KC CARE Clinic

NCT07473778

/ Not yet recruitingNot Applicable

Pioneering Research to Optimize Pre-exposure Prophylaxis (PrEP) Expansion With Lenacapavir (LEN)

The goal of this observational study is to generate real-life information on the use of lenacapavir (LEN, YEZTUGO®, (YTG)) for pre-exposure prophylaxis (PrEP) across diverse clinical settings in the United States. The study will characterize how PrEP is initiated, used, and discontinued in routine clinical practice when LEN is added as PrEP option and will evaluate persistence on LEN PrEP.
The primary objective of this study is to evaluate real-life persistence on LEN PrEP at Week 52 in diverse clinical settings in the United States.

Start Date01 Mar 2026

Sponsor / Collaborator

Gilead Sciences, Inc.

100 Clinical Results associated with Cabotegravir sodium

100 Translational Medicine associated with Cabotegravir sodium

100 Patents (Medical) associated with Cabotegravir sodium

1,187

Literatures (Medical) associated with Cabotegravir sodium

31 Dec 2026·JOURNAL OF DERMATOLOGICAL TREATMENT

Long-term efficacy and tolerability of clindamycin phosphate 1.2%/adapalene 0.15%/benzoyl peroxide 3.1% gel for acne: pooled results from two 6-month studies

Article

Author: Tanghetti, Emil A. ; Wroblewski, Karol ; Ghannoum, Mahmoud ; Harper, Julie C. ; Kircik, Leon H. ; Baldwin, Hilary ; Draelos, Zoe D. ; Gold, Linda Stein

AIM:

Given the chronic nature of acne, two 6-month studies were conducted to evaluate the long-term efficacy and tolerability of clindamycin phosphate 1.2%/adapalene 0.15%/benzoyl peroxide (BPO) 3.1% gel (CAB)-the only approved triple-combination acne topical-and its effects on scarring/dyspigmentation in participants with moderate to severe acne.

MATERIALS AND METHODS:

Data were pooled from 2 identical, open-label, single-center studies conducted in participants (N = 50) aged ≥12 years with Investigator's Global Assessment (IGA) score of 3/4. Endpoints included change from baseline in IGA score, inflammatory/noninflammatory lesions, skin appearance (dryness, postinflammatory hyperpigmentation [PIH], postinflammatory erythema [PIE]), and scarring. Adverse events and tolerability (itching, burning, redness, swelling) were assessed.

RESULTS:

At week 24, 67% of participants achieved treatment success, and significant reductions from baseline in inflammatory (88%) and noninflammatory (68%) lesions were observed (p < 0.001, both). Significant reductions in scarring (33%), investigator- and participant-assessed PIH (71%; 78%, respectively), and PIE (77%; 77%, respectively) were demonstrated (p < 0.001, all). Most participants (>70%) reported no tolerability issues throughout the studies. Seven adverse events occurred; 4 were related to CAB, and 3 led to study discontinuation (BPO allergy [n = 2], irritant contact dermatitis to BPO [n = 1]).

CONCLUSIONS:

These findings suggest that CAB is an appropriate and effective topical option for the long-term treatment of acne vulgaris.

01 Jun 2026·BIOCHEMICAL PHARMACOLOGY

Novel 1,2,3-triazole-based compound triggers apoptosis through DNA damage response involving ATM/ATR signaling in liver cancer cells

Article

Author: Lu, Yao ; Liu, Ling ; Li, Yiying ; Cheng, Sisi ; Zhang, Yining

1,2,3-Triazole-substituted cabotegravir analogues, i.e., KJ-9, have been developed as lead structures to explore their potential as antitumor agents. The new analogue exhibited significant anti-proliferative activity against various human cancer cell lines, with particularly strong effects on the HepG2 and HCCLM3 liver cancer lines, as it induced a marked loss of colony-forming ability and triggered apoptosis upon KJ-9 exposure. Furthermore, treatment with KJ-9 increased the Bax-to-Bcl-2 protein ratio and activated cleaved caspase-9, caspase-3, and poly(ADP-ribose) polymerase (PARP). Meanwhile, KJ-9 treatment induced a blockage in the cell cycle (G2/M), increased DNA damage levels, and induced the accumulation of histone variant H2AX (γ-H2AX) protein. Furthermore, there was strong induction of p-ATM and p-ATR proteins, along with their downstream effectors p-CHK1 and p-CHK2. Additionally, KJ-9 treatment increased phosphorylation levels of the tumor suppressor protein p53 and inhibited components of the PI3K/AKT pathway. Although it did not significantly affect AKT phosphorylation, the ATM/ATR inhibitor CGK733 significantly reversed KJ-9-induced upregulation of p-ATM, p-ATR, p-p53, γ-H2AX, and activated caspase-3. Moreover, reactive oxygen species (ROS) were generated in greater quantities by KJ-9 treatment. After KJ-9 treatment, ROS were suppressed by the addition of the antioxidant N-Acetylcysteine (NAC), leading to increased levels of p-AKT and reduced levels of p-ATM, p-ATR, p-p53, cleaved caspase-3, and γ-H2AX. These findings suggest that KJ-9 promotes oxidative stress, which further inhibits AKT activation while activating the ATM/ATR pathway, leading to p53 accumulation, sustained DNA damage responses, G2/M-phase cell cycle arrest, and apoptosis in both HepG2 cells and HCCLM3 cells.

09 Apr 2026·Sexual Health

Implementation of a Hospital in the Home model for delivery of long-acting injectable antiretroviral therapy to people living with HIV: development, integration and early experience

Article

Author: Trevillyan, Janine ; Dowling, Ray ; Rose, Morgan ; Lam, Connie ; Bangham, Madeleine ; Narayanasamy, Shanti ; Sullivan, Angela

Background:

Long-acting injectable cabotegravir/rilpivirine provides an alternative to daily oral antiretroviral therapy for people living with HIV, but is limited by its clinic-based delivery model. The aim of this study was to describe the implementation and early outcomes of a Hospital in the Home (HITH) program delivering long-acting injectable antiretroviral therapy within an Australian tertiary health service.

Methods:

A structured protocol for HITH-based delivery of cabotegravir/rilpivirine was developed at a single tertiary centre in Melbourne, Australia. The program was established through collaboration between infectious diseases clinicians, HITH physicians, nursing leadership and pharmacy. Processes were designed for patient selection, induction dosing, medication storage, cold-chain transport, clinical documentation and escalation of care. HITH staff received targeted training in HIV care, injection technique and stigma-sensitive communication. Following the first dose in clinic, subsequent injections were administered at home every 8 weeks, with pre-visit telephone assessments, post-dose telehealth reviews and routine pathology monitoring.

Results:

The program was integrated into existing HITH infrastructure without additional resources. One patient has completed five treatment doses, all delivered safely within dosing timeframes. Laboratory monitoring confirmed continued viral suppression. Nursing staff reported high satisfaction, describing the model as patient-centred and professionally rewarding. Operationally, coordination between HITH pharmacy, nursing and infectious diseases teams was efficient and sustainable.

Conclusion:

HITH delivery of cabotegravir/rilpivirine is feasible, safe and well accepted, providing a scalable, decentralised model for HIV treatment in Australia.

168

News (Medical) associated with Cabotegravir sodium

27 Feb 2026

·www.drugs.com

Monthly Cabotegravir-Rilpivirine Injections Superior to Standard Oral ART for HIV With Adherence Challenges

FRIDAY, Feb. 27, 2026 -- Monthly injections of long-acting cabotegravir-rilpivirine are superior to standard oral antiretroviral therapy (ART) in persons with human immunodeficiency virus ( HIV ) and medication adherence challenges, according to a study published online Feb. 18 in the New England Journal of Medicine . Aadia I. Rana, M.D., from the University of Alabama at Birmingham, and colleagues enrolled 453 persons with HIV who had inadequate adherence to ART (a persistent HIV-1 RNA level of >200 copies per milliliter or loss to follow-up) to 24 weeks of adherence support, conditional economic incentives, and standard care with oral ART as part of step 1. Then, in step 2, the 306 participants achieving an HIV-1 RNA level of ≤200 copies per milliliter were randomly assigned to continue standard care (154 participants) or switch to monthly injections of long-acting cabotegravir plus rilpivirine with or without oral lead-in therapy (152 participants). The researchers reported that step 2 randomization was stopped early on the basis of the superiority of cabotegravir-rilpivirine to standard care at a prespecified analysis. By week 48, the cumulative incidence of regimen failure was 22.8 percent in the cabotegravir-rilpivirine group and 41.2 percent in the standard-care group. For adverse events, the cumulative incidence was 43.5 percent in the cabotegravir-rilpivirine group versus 42.4 percent in the standard-care group. Two participants in each group developed resistance-associated mutations with confirmed virologic failure. "These findings have the potential to validate a long-acting approach for this additional group of patients and could make a significant difference to people living with HIV and our goal of ending the epidemic," Kimberly Smith, M.D., head of research & development at ViiV Healthcare, said in a statement. Several authors disclosed ties to ViiV Healthcare, the maker of cabotegravir-rilpivirine. Abstract/Full Text Editorial (subscription or payment may be required)

Clinical ResultPhase 2siRNA

26 Feb 2026

·www.fiercepharma.com

GSK's ViiV confirms staying power of long-acting HIV treatment Cabenuva in adolescents

The IMPAACT 2017 study showed adolescents using Cabenuva largely preferred the injections to daily oral therapies. As GSK’s HIV unit ViiV Healthcare grapples with a new rival in the injectable HIV prevention and treatment field, the company is reinforcing the staying power of its long-acting treatment Cabenuva in adolescents.ViiV originally tested its long-acting injectable Cabenuva, made from ViiV’s cabotegravir and Johnson & Johnson’s Edurant (rilpivirine), as an every-two-month HIV treatment in children 12 years and older in its Mocha (More Options for Children and Adolescents) study, born from a collaboration with the International Maternal Pediatric Adolescent AIDS Clinical Trials Network (IMPAACT). A Week 16 interim analysis of the study helped the company secure an expanded FDA approval covering the younger population of HIV patients in 2022, marking another milestone for what was then the only marketed long-acting HIV treatment regimen. Since then, Gilead Sciences’ twice-yearly lenacapavir has entered the scene as both a long-acting pre-exposure prophylaxis med and as a treatment for multidrug-resistant HIV.With Gilead looking to edge in further on the long-acting treatment market by testing lenacapavir in the broader HIV population, ViiV is sharpening the case for Cabenuva with 96-week data from its Mocha study, also referred to as IMPAACT 2017. As ViiV announced at the 33rd Conference on Retroviruses and Opportunistic Infections (CROI) in Colorado this week, 94.4% of virologically suppressed adolescents with HIV who switched from a daily oral treatment to every-two-month Cabenuva maintained viral suppression at Week 96. The study enrolled adolescents between the ages of 12 and 18.More than 97% of the trial participants indicated they preferred long-acting injections over daily oral antiretrovirals at “all weeks evaluated,” ViiV said in a Feb. 24 press release, with 100% of the group expressing the preference for injections at Week 96 specifically. For many in the 144-person study, the treatment period was “the first time in their lives they did not have to take an oral HIV medicine every day,” co-lead investigator Aditya Gaur, M.D., said in a statement. Meanwhile, ViiV is looking to grow the reach of its long-acting treatment with its IMPAACT 2036 study in younger children between the ages of 2 and 12. The study is in very early stages, but the company recently secured the first pharmacokinetic and safety evidence that can help inform the remainder of the trial, ViiV said at CROI. Elsewhere, ViiV hopes to reach new ultralong-acting heights with its investigational lotivibart, a broadly neutralizing antibody that it has paired with Cabenuva in studies. Newly presented 12-month data on the treatment regimen showed efficacy when dosed every four months, but the company hopes to eventually progress the trial to a twice-yearly dosing interval. Long-acting Cabenuva made up 55% of total HIV growth for GSK in 2025, raking in yearly sales of 1.4 billion pounds sterling ($1.9 billion).

Clinical StudyClinical ResultDrug Approval

26 Feb 2026

·www.biospace.com

ViiV Healthcare reports positive 12-month data showing investigational bNAb lotivibart (N6LS) maintains high levels of viral suppression in long-acting HIV treatment regimen

94% of adults on stable therapy maintained viral suppression with intravenous lotivibart dosed every four months in combination with long-acting cabotegravir These phase IIb results reinforce lotivibart’s ultra long-acting potential, with the trial progressing to evaluate a twice-yearly intravenous dosing interval LONDON--(BUSINESS WIRE)--ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders,* today announced positive 12-month interim efficacy and tolerability data from the phase IIb EMBRACE study. 1 In adults living with HIV on stable therapy, a regimen of lotivibart (N6LS), a broadly neutralising antibody, administered every four months combined with monthly intramuscular (IM) long-acting cabotegravir (CAB LA), maintained viral suppression in 94% of participants receiving lotivibart intravenously (IV) and 82% subcutaneously (SC), compared with 88% in the standard of care group. These favourable data reinforce lotivibart’s ultra long-acting potential (dosing every four months or longer) and support the progression of the study, which will evaluate a twice-yearly IV dosing interval for lotivibart. Results were presented today at the 33 rd Conference on Retroviruses and Opportunistic Infections (CROI 2026) in Denver, Colorado. Kimberly Smith, M.D., MPH, Head of Research & Development at ViiV Healthcare, said: “These positive 12-month data from EMBRACE strengthen the evidence that lotivibart has the potential to be a part of an ultra long-acting HIV treatment regimen and support our efforts to evaluate lotivibart in a twice-yearly dosing interval. These results build on our legacy of developing innovative long-acting options for HIV treatment that offer greater choice for people living with HIV.” At the 12‑month interim analysis, lotivibart combined with CAB LA maintained viral suppression in a high proportion of adults living with HIV on stable therapy, with confirmed virologic failure observed in two participants (4%; n=2/50) from the IV group and three participants (6%; n=3/49) in the SC group, compared to one (4%; n=1/26) receiving a daily oral standard of care. Lotivibart was generally well tolerated, with participants in both groups reporting high acceptability through month 12. Mean perception of injection (PIN) scores for “bother of ISRs,” “physical impact,” “sleep” and “acceptability” remained “very acceptable” to “totally acceptable” throughout the study in both groups. Adverse events related to lotivibart were less common in the IV group (24%; n=12/50) compared with the SC group (53%; n=26/49). Higher grade (grade 3-4) infusion-site reactions were reported in 16% (n=8/49) of participants in the SC group, while none were reported in the IV group. These findings build on the six-month EMBRACE data presented at CROI 2025, which first showed that lotivibart, administered every four months in combination with monthly CAB LA, effectively maintained an undetectable viral load in adults living with HIV on stable therapy. About ViiV Healthcare ViiV Healthcare is a global specialist HIV company established in November 2009 by GSK (LSE: GSK) and Pfizer (NYSE: PFE) dedicated to delivering advances in treatment and care for people living with HIV and for people who could benefit from HIV prevention. Shionogi became a ViiV shareholder in October 2012. The company’s aims are to take a deeper and broader interest in HIV and AIDS than any company has done before and take a new approach to deliver effective and innovative medicines for HIV treatment and prevention, as well as support communities affected by HIV. For more information on the company, its management, portfolio, pipeline, and commitment, please visit viivhealthcare.com . About GSK GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at gsk.com . Cautionary statement regarding forward-looking statements GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described in the “Risk Factors” section in GSK’s Annual Report on Form 20-F for 2024, and GSK’s Q4 Results for 2025. Registered in England & Wales: GSK plc ViiV Healthcare Limited No. 3888792 No. 06876960 Registered Office: 79 New Oxford Street ViiV Healthcare Limited London GSK Medicines Research Centre WC1A 1DG Gunnels Wood Road, Stevenage United Kingdom SG1 2NY *On 20 January 2026, GSK plc and Shionogi & Co., Ltd announced that they have reached agreement together with Pfizer Inc. for the economic interest in ViiV Healthcare Limited currently held by Pfizer to be replaced with an investment by Shionogi. Completion of the transaction is subject to certain regulatory clearances in relevant markets, and is expected to occur during the first quarter of 2026. References 1 CP. Rolle et al. Maintenance of HIV Suppression at 12 Months With VH3810109 (N6LS) Q4M + CAB LA QM: The EMBRACE Study. Presented at the 33 rd Conference on Retroviruses and Opportunistic Infections (CROI). February 2026. Contacts ViiV Healthcare enquiries: Media: Kate Senter, +44 (0) 77 9670 7446 (London) Melinda Stubbee, +1 919 491 0831 (North Carolina) GSK enquiries: Media: Tim Foley, +44 (0) 20 8047 5502 (London) Sarah Clements, +44 (0) 20 8047 5502 (London) Kathleen Quinn, +1 202 603 5003 (Washington, DC) Alison Hunt, +1 540 742 3391 (Washington, DC) Investor Relations: Constantin Fest, +44 (0) 7831 826525 (London) James Dodwell, +44 (0) 20 8047 2406 (London) Mick Readey, +44 (0) 7990 339653 (London) Steph Mountifield, +44 (0) 7796 707505 (London) Sam Piper, +44 (0) 7824 525779 (London) Jeff McLaughlin, +1 215 751 7002 (Philadelphia) Frannie DeFranco, +1 215 751 3126 (Philadelphia)

Clinical ResultPhase 2

100 Deals associated with Cabotegravir sodium

External Link

KEGG	Wiki	ATC	Drug Bank
D10548 D10549	Cabotegravir sodium	J05AR	DB11751

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
HIV Infections	Canada	ViiV Healthcare Ltd.	21 Sep 2020

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
HIV-Associated Lipodystrophy Syndrome	Phase 1	United States	GSK Plc	01 May 2013
Hepatitis	Phase 1	United States	ViiV Healthcare Ltd.	01 Nov 2011
Herpesviridae Infections	Phase 1	-	ViiV Healthcare Ltd.	01 Sep 2010

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03635788 (LATITUDE, Pubmed) Manual	Phase 3	HIV Infections	306	Cabotegravir+rilpivirine	weougmggrj(avplefxhiz) = mixjjidqtg koabapfztg (pcygsvywvq ) View more	Positive	26 Feb 2026
				Standard care	weougmggrj(avplefxhiz) = sjiprwanus koabapfztg (pcygsvywvq ) View more
NCT06250504 (LAPIS, Pubmed \| BMC Public Health)	Phase 3	HIV Infections	40	choice of PrEP modality choices through community-based SRH services	yiafbpfhge(eycesploja) = hkpzwcbcum yarmdinpsz (rdbkoygukq ) View more	Positive	20 Jan 2026
NCT05374525 (PILLAR, CTgov)	Phase 4	HIV Infections	287	Cabotegravir OLI (Dynamic Implementation (DI) - PSP)	jzwsqglhvh(fgoefagjqb) = netkeyadct madcrdgtww (zaryhjfzgp, 0.77) View more	-	15 Dec 2025
				Cabotegravir OLI (Routine Implementation (RI) - PSP)	jzwsqglhvh(fgoefagjqb) = sbmselqkng madcrdgtww (zaryhjfzgp, 0.70) View more
NCT04542070 (SOLAR, Pubmed \| J Infect Chemother)	Phase 3	HIV Infections	396	Cabotegravir+rilpivirine (CAB+RPV) LA Q2M with a 1-month optional once-daily OLI of CABRPV) LA Q2M with a 1-month optional once-daily OLI of CAB+RPV	xyfkcfoupb(gjrbkotanq) = jozezknzhx ugkaugdtel (auraxlolfo ) View more	Positive	01 Dec 2025
				Bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF)	xyfkcfoupb(gjrbkotanq) = azxslrdqni ugkaugdtel (auraxlolfo ) View more
NCT05917509 (VOLITION, BusinessWire) Manual	Phase 3	HIV Infections	145	Vocabria + Rekambys (cabotegravir + rilpivirine LA (CAB+RPV LA))	xlwhzhogmr(vkoayulzbh) = miifqqqmgc qossohktay (afqzbqgsxk ) View more	Positive	14 Jul 2025
NCT04542070 (SOLAR, Pubmed \| J Infect Chemother)	Phase 3	-	670	Long-Acting Cabotegravir + Rilpivirine (CAB+RPV LA)	ylqgxmjeqt(drxejzqdlo) = mmbvbkplqx mvcgjryasg (lhevdjocdj ) View more	Positive	01 Jul 2025
				Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF)	ylqgxmjeqt(drxejzqdlo) = gapnokxbai mvcgjryasg (lhevdjocdj ) View more
NCT03635788 (LATITUDE \| LATITUDE, CTgov)	Phase 3	HIV Infections	456	Oral CAB+CAB-LA Maintenance Dose+RPV-LA Loading Dose (Step 2 Arm A: LA ART)	jqmelwrfkz = fatqhugloz vikwagacpr (jayqzgbpqh, xeujvrdfvj - ghrfflslxh) View more	-	24 Apr 2025
				Standard of Care (SOC) Oral ART (Step 2 Arm B: SOC)	jqmelwrfkz = zybzxdwqsi vikwagacpr (jayqzgbpqh, tpipejzmuo - joopsdqrzt) View more
NCT04542070 (SOLAR, Pubmed \| J Acquir Immune Defic Syndr)	Phase 3	HIV Infections	687	Cabotegravir + Rilpivirine LA	mhaxcxfstf(dqjwcxzyks) = xjflyxejme kkvemgmvnj (lsjzlssqic, -4.50 to 4.00)	Positive	01 Apr 2025
				Bictegravir/Emtricitabine/Tenofovir Alafenamide	stkulvabje(palvoabiwp) = btgcdfzjgh pghuqourxy (ljcvbcxdlx, -2.30 to +1.95) View more
NCT03497676 (IMPAACT 2017/MOCHA, Pubmed \| Lancet HIV)	Phase 1/2	HIV Infections	139	Long-acting Injectable Cabotegravir 600 mg + Long-acting Injectable Rilpivirine 900 mg	rdsywzenvr(hbfulrxlfa) = 10.8% [95% CI 6.2-17.2] of all 139 participants in the evaluable analysis population had at least one adverse event of grade 3 or above by week 24 svftzdixgc (hfqltpmtgv ) View more	Positive	01 Mar 2025
NCT04692077 (CTgov)	Phase 2	HIV Infections	9	CAB LA+Tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) tablet	iefeoxajzr(xlcsnbogkh) = bkrbsyftho tlhqiejgje (mnvoweegbm, 1.3) View more	-	29 Jan 2025

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis